证券代码：603168 证券简称：莎普爱思 公告编号：临 2019-032 浙江莎普爱思药业股份有限公司 | --- | --- | |----------------------------------------------------------------------|-------| | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | 根据中国证券监督管理委员会浙江监管局下发的《浙江辖区上市公司投资者 接待日工作指引》的要求，为进一步提升浙江莎普爱思药业股份有限公司（以下 简称"莎普爱思"、"公司"）的治理水平，加强投资者关系管理，增进公司与 广大投资者的沟通与交流，公司特于 2019 年 5 月 8 日在上海证券交易所网站 (www.sse.com.cn)上披露了《莎普爱思关于举办投资者接待日活动的公告》（公 告编号：临 2019-028）。 公司本次投资者接待日活动于 2019 年 5 月 21 日（星期二）上午 10:00 至 11:30 在浙江省平湖市经济开发区新明路 1 ...

证券代码：603168 证券简称：莎普爱思 公告编号：临 2019-028 浙江莎普爱思药业股份有限公司 | --- | --- | |----------------------------------------------------------------------|--------------------------------------------------------------------| | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | 根据中国证券监督管理委员会浙江监管局下发的《浙江辖区上市公司投资者 接待日工作指引》的要求，为进一步提升浙江莎普爱思药业股份有限公司（以下 简称"公司"）的治理水平，加强投资者关系管理，增进公司与广大投资者的沟 通与交流，公司定于2019年5月21日上午举办投资者接待日活动。现将有关事项 公告如下： 1、活动时间：2019年5月21日（星期二）上午10：00至11：30 2、活动地点： 浙江省平湖市经济开发区新明路1588号浙江 ...

Financial Performance - The company's operating revenue for 2018 was ¥607,437,969.19, a decrease of 35.30% compared to ¥938,883,499.80 in 2017 [24]. - The net profit attributable to shareholders for 2018 was -¥126,474,321.41, representing a decline of 186.42% from ¥146,356,420.23 in 2017 [24]. - The cash flow from operating activities increased by 120.25% to ¥100,373,495.63 in 2018, compared to ¥45,572,205.17 in 2017 [24]. - The company's total assets decreased by 11.81% to ¥1,648,594,028.08 at the end of 2018, down from ¥1,869,408,347.88 at the end of 2017 [24]. - The basic earnings per share for 2018 was -¥0.39, a decrease of 186.67% from ¥0.45 in 2017 [25]. - The weighted average return on equity for 2018 was -8.06%, a decrease of 17.10 percentage points from 9.04% in 2017 [25]. - The company reported a significant decline in revenue from eye drops by 52.58% and traditional Chinese medicine by 68.95% due to negative media coverage in December 2017 [26]. - The company recognized goodwill impairment losses of ¥178,157,200 related to its subsidiary, which significantly impacted the net profit for the reporting period [26]. Audit and Compliance - The company received a standard unqualified audit report from Tianjian Accounting Firm, ensuring the accuracy and completeness of the financial report [5]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties during the reporting period [8]. - The company has not reported any violations of decision-making procedures regarding external guarantees [8]. - The company emphasizes the importance of investor awareness regarding investment risks associated with forward-looking statements in the report [7]. Business Operations - The company expanded its business scope to include the production and sale of disinfectant products, as approved in meetings held in August and September 2018 [32]. - The company maintains stable relationships with multiple suppliers to ensure the stability of raw material supply and pricing [37]. - The company's marketing network covers most provinces and municipalities in China, enhancing its market responsiveness [47]. - The company opened a flagship store on Tmall to enhance online sales of its products [55]. Research and Development - The company emphasizes R&D and has established partnerships with universities to strengthen its product development capabilities [48]. - The company invested CNY 26.56 million in R&D, a decrease of 9.14% year-on-year [63]. - The company has obtained 6 invention patents and 14 design patents by the end of 2018, indicating a strong focus on innovation [130]. - The company is actively developing multiple generic drug consistency evaluation projects, including the consistency evaluation of Benzalkonium Chloride Eye Drops [129]. - The company is focusing on ophthalmic drugs as its main research line, aiming to develop proprietary pharmaceutical products [128]. Market and Industry Trends - The pharmaceutical industry in China achieved a main business income of CNY 2,398.63 billion in 2018, with a year-on-year growth of 12.6% [41]. - The total profit of the pharmaceutical industry was CNY 309.42 billion, with a year-on-year growth of 9.5% [41]. - The company’s core product, Shapu Aisi eye drops, held a market share of 21.58% in the cataract medication market in China [43]. - The projected market size for cataract eye drops in China over the next five years is estimated to be between 1.5 billion and 3 billion yuan [111]. Future Outlook - The company anticipates achieving a revenue of 705 million yuan and a net profit of 53 million yuan in 2019, focusing on internal efficiency and cost reduction [176]. - The company plans to enhance market expansion by adjusting sales strategies, increasing marketing efforts, and improving collaboration with key pharmacy chains [177]. - The company aims to accelerate new product development, prioritizing the consistency evaluation of Benzalkonium Chloride Eye Drops and advancing other products like Cefixime Granules and Levofloxacin Tablets [178]. - The company recognizes the ongoing challenges and opportunities in the pharmaceutical industry due to regulatory changes and market dynamics, which will require strategic adjustments [173]. Profit Distribution - The company has established a continuous and stable profit distribution policy, committing to distribute at least 30% of the annual distributable profits in cash dividends [199]. - The company emphasizes the importance of considering the opinions of independent directors and public investors when adjusting profit distribution policies [199]. - The company’s profit distribution plan aligns with its articles of association and commitments made during the IPO, benefiting shareholders, especially small and medium investors [200].

一、 重要提示 二、 公司基本情况 公司代码：603168 公司简称：莎普爱思 浙江莎普爱思药业股份有限公司 2019 年第一季度报告 | 一、重要提示 | | 3 | | --- | --- | --- | | 二、公司基本情况 | | 3 | | 三、重要事项 | | 6 | | 四、附录 | | 9 | 浙江莎普爱思药业股份有限公司 2019 年第一季度报告 2.1 主要财务数据 | | 本报告期末 | 上年度末 | 本报告期末比上年度末 | | | --- | --- | --- | --- | --- | | | | | 增减(%) | | | 总资产 | 1,642,608,778.89 | 1,648,594,028.08 | | -0.36 | | 归属于上市公 | 1,500,618,473.38 | 1,481,179,086.85 | | 1.31 | | 司股东的净资 | | | | | | 产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | 经营活动产生 | 46,256,242.12 | 89,934,958.46 | | ...

2018 年第三季度报告 浙江莎普爱思药业股份有限公司 2018 年第三季度报告 1 / 24 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 12 | 2018 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人陈德康、主管会计工作负责人张群言及会计机构负责人（会计主管人员）张群言 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 公司代码：603168 公司简称：莎普爱思 二、 公司基本情况 2.1 主要财务数据 3 / 24 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年 度末增减(%) 总资产 1,803,046,321.68 1,869,408,347.88 -3.55 归属于上市公司股东的净 资产 1,685,577,37 ...

2018 年半年度报告 公司代码：603168 公司简称：莎普爱思 浙江莎普爱思药业股份有限公司 603168 2018 年半年度报告 1 / 115 2018 年半年度报告 重要提示 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 不适用 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的承诺，敬请投资者注意 投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 公司已在本报告中详细描述存在的风险，请参阅"第四节经营情况的讨论与分析中二、其他 披露事项中（二）可能面对的风险"相关内容。报告期内，《中国证券报》、《上海证券报》、 《证券时报》、《证券日报》和上海证券交易所网站（www.sse.com.cn）为本公司指定的信息披 露媒体，本公司所有信息均以在上述选定媒体刊登的信息为准，敬请投资者注意投资风险。 十、 其他 □适用 √不适用 2 / 115 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不 ...

Financial Performance - Revenue decreased by 15.52% to CNY 186,147,655.81 compared to the previous year[6] - Net profit attributable to shareholders decreased by 18.40% to CNY 40,852,483.69 year-on-year[6] - Basic earnings per share decreased by 20.00% to CNY 0.16 compared to the same period last year[6] - The weighted average return on equity decreased by 0.65 percentage points to 2.44%[6] - The company reported a net profit margin decline due to reduced revenue and higher costs[34] - The company's operating revenue for Q1 2018 was CNY 181,129,905.51, a decrease of 3.99% compared to CNY 187,890,079.43 in the same period last year[37] - Net profit for Q1 2018 was CNY 49,226,767.30, an increase of 11.88% compared to CNY 44,116,615.08 in Q1 2017[38] - The total profit for Q1 2018 was CNY 57,906,761.49, an increase from CNY 51,894,408.25 in Q1 2017[38] - The company incurred tax expenses of CNY 8,679,994.19 in Q1 2018, compared to CNY 7,777,793.17 in the previous year[38] Cash Flow and Liquidity - Operating cash flow increased significantly by 180.06% to CNY 89,934,958.46 compared to the same period last year[6] - Cash and cash equivalents decreased by 45.60% to CNY 238,479,657.47 due to investment in financial products[15] - Cash flow from purchasing goods and services decreased by 34.39% to ¥37,534,308.26, attributed to the company's self-production of a specific product[17] - The company reported a 99.25% decrease in cash received from investment activities, totaling ¥131,523,315.07, due to the redemption of financial products[17] - Cash payments for investment activities increased by 35% to ¥400,000,000, reflecting a rise in the purchase of financial products[17] - The company's cash and cash equivalents decreased to ¥238,479,657.47 from ¥438,414,623.27, indicating a significant reduction in liquidity[27] - The net cash flow from operating activities for the first quarter of 2018 was ¥89,934,958.46, a significant increase from ¥32,112,851.21 in the previous year, representing a growth of 179.5%[41] - Total cash inflow from operating activities amounted to ¥278,796,785.85, compared to ¥262,646,522.94 in the same period last year, indicating a year-over-year increase of 6.5%[41] - Cash outflow from operating activities decreased to ¥188,861,827.39 from ¥230,533,671.73, reflecting a reduction of 18.1%[41] - The ending cash and cash equivalents balance decreased to ¥238,479,657.47 from ¥497,521,701.60, a decline of 52.2%[42] Assets and Liabilities - Total assets increased by 0.49% to CNY 1,878,521,414.65 compared to the end of the previous year[6] - Net assets attributable to shareholders increased by 2.47% to CNY 1,698,135,507.15 year-on-year[6] - Total liabilities amounted to CNY 180,385,907.50, a decrease from CNY 212,125,324.42[29] - Total equity increased to CNY 1,731,996,115.82 from CNY 1,682,769,348.52, representing a growth of 2.9%[33] - Current assets totaled CNY 955,864,003.95, an increase from CNY 909,246,442.63 at the beginning of the year[32] - The total non-current assets were CNY 932,574,245.29, slightly down from CNY 938,704,501.46[32] Investment Activities - Investment income decreased by 45.16% to CNY 1,437,089.69 due to fewer maturing financial products this period[16] - The company has increased its investment limit for low-risk financial products to a total of ¥4 billion, allowing for more flexible fund management[19] - Cash inflow from investment activities was recorded at ¥131,523,315.07, down from ¥202,620,424.66, a decrease of 35.1%[41] - Cash outflow from investment activities increased significantly to ¥421,393,239.33 from ¥222,079,024.01, marking an increase of 89.9%[41] Operational Highlights - The company has completed the consistency evaluation of a specific eye drop product, with all quality indicators aligning with the original drug[22] - The company is actively pursuing the consistency evaluation work for its eye drop product in compliance with regulatory requirements[22] - The company plans to focus on expanding its market presence and developing new products in the upcoming quarters[34]

Financial Performance - The company achieved a net profit of ¥155,759,326.52 for the year 2017, with a distributable net profit of ¥140,183,393.87 after a 10% legal reserve allocation[6]. - A cash dividend of ¥2.00 per 10 shares is proposed, totaling ¥49,629,615.20, which represents 35.40% of the distributable net profit for 2017[6]. - The company's operating revenue for 2017 was approximately ¥938.88 million, a decrease of 4.07% compared to ¥978.73 million in 2016[24]. - The net profit attributable to shareholders was approximately ¥146.36 million, down 46.92% from ¥275.72 million in 2016[24]. - The cash flow from operating activities was approximately ¥45.57 million, a significant decline of 84.52% compared to ¥294.33 million in 2016[24]. - Basic earnings per share decreased by 51.24% to ¥0.59 in 2017 from ¥1.21 in 2016[25]. - The weighted average return on equity dropped to 9.04%, a decrease of 18.59 percentage points from 27.63% in 2016[25]. - The company reported a goodwill impairment loss of ¥50.63 million in the fourth quarter due to the failure to meet profit commitments from a subsidiary[27]. - The total assets at the end of 2017 were approximately ¥1.87 billion, an increase of 1.48% from ¥1.84 billion in 2016[24]. - The net assets attributable to shareholders increased by 3.95% to approximately ¥1.66 billion at the end of 2017[24]. Shareholder Returns - The company plans to maintain a cash dividend ratio of no less than 30% of the distributable profits for the years 2017 to 2019[63]. - The total number of shares for the dividend distribution is based on 248,148,076 shares[6]. Risk Management - The company emphasizes the importance of risk awareness in future plans and development strategies[7]. - The company has detailed risk factors in the report, which investors should consider[9]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[8]. Market and Competition - The company operates in a competitive environment, with a focus on innovation and strong marketing capabilities to enhance its competitive advantage[1]. - The company faced challenges in 2017 due to market competition and external media scrutiny affecting its operational performance[51]. - The cataract drug market in China was valued at 3.415 billion yuan in 2017, showing a year-on-year decline of 5.30%[7]. - The aging population in China is projected to exceed 260 million by 2030, leading to an increase in cataract patients and a growing demand for related medications[6]. Research and Development - The company emphasizes R&D and has built partnerships with institutions like Southeast University and China Pharmaceutical University to strengthen its product development capabilities[48]. - The company has initiated the consistency evaluation of the quality and efficacy of its eye drops, with preliminary results showing alignment with the original drug[59]. - The company is actively engaged in partnerships for research and development, combining independent R&D with industry-academia collaboration[134]. - The company has received clinical trial approval for Omeprazole Sodium Bicarbonate, demonstrating progress in its product pipeline[134]. - The company is conducting Phase II clinical studies for its drug targeting diabetic nephropathy, showcasing its commitment to addressing chronic health issues[135]. Product Development - The company expanded its business scope to include the production and sales of medical devices, approved in October 2017[31]. - The company plans to continue expanding its traditional Chinese medicine product line, which has shown significant growth[74]. - The company is actively pursuing consistency evaluations and new product developments in compliance with national regulations, aiming to enhance its product portfolio and market position[156]. - The company is focusing on enhancing its product portfolio and core competitiveness through continuous R&D investment[150]. Marketing and Sales - The company has established a strong marketing network covering most provinces and cities in China, enhancing its market responsiveness[47]. - The company has engaged in nationwide and regional public welfare activities to enhance brand awareness and reputation[167]. - The company’s sales model for OTC products involves direct sales to distributors, who then sell to retail pharmacies, ensuring effective market coverage[160]. - The company is developing several new drugs, including a new generation of anti-cataract drugs and a dry eye treatment, with various stages of research and development ongoing[156]. Financial Management - The company’s financial expenses decreased by 162.00% due to the absence of interest expenses this period[87]. - The procurement amount from the top five suppliers was CNY 8,150.31 million, accounting for 47.76% of total procurement, with the largest supplier contributing CNY 5,088.47 million[85]. - The company’s total R&D investment was CNY 29,234,720.68, representing 3.11% of total revenue, with 124 R&D personnel making up 6.08% of the total workforce[90]. Challenges and Future Outlook - The company will continue to face challenges from industry reforms, rising costs, and increased competition in the pharmaceutical sector[182]. - The pharmaceutical industry faces significant risks from government policies, including drug price reductions and medical insurance cost control, which could limit sales growth[190]. - New drug development poses high risks due to long cycles and substantial investments; the company plans to improve project decision-making and market research[194]. - The company is exploring acquisition opportunities to diversify its product portfolio and reduce reliance on single products[199].

2017 年第三季度报告 公司代码：603168 公司简称：莎普爱思 浙江莎普爱思药业股份有限公司 2017 年第三季度报告 1 / 22 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 11 | 2017 年第三季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 3 / 22 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人陈德康、主管会计工作负责人张群言及会计机构负责人（会计主管人员）张群言 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 2017 年第三季度报告 非经常性损益项目和金额 √适用 □不适用 单位：元 币种：人民币 | 项目 | 本期金额 | | 年初至报告期末 | 说明 | | --- | ...

Capital Structure and Shareholder Information - The company completed a non-public offering of 13,873,626 shares, increasing its registered capital from 163.375 million RMB to 177.248626 million RMB[18]. - Following the 2016 profit distribution plan, the total number of shares increased from 177,248,626 to 248,148,076 shares, with a cash dividend of 4.70 RMB per 10 shares[19]. - The company has not proposed any profit distribution or capital reserve transfer plans for the reporting period[5]. - The actual controller, Wang Quanping, committed to not increasing his shareholding in the company for 12 months starting from November 4, 2016, and plans to reduce his holdings by up to 10 million shares[77]. - Shanghai Jingxing Industrial Investment Co., Ltd. also plans to reduce its shareholding by up to 10 million shares within 12 months, including an unfinished reduction of 8 million shares from a previous plan[77]. - The company committed to maintaining a cash dividend ratio of no less than 30% of the distributable profit for the years 2014 to 2016, although no dividends were distributed in 2017[78]. - The company has strategic investors, including China United Property Insurance Co., Ltd., which holds 3,846,153 shares under a lock-up agreement until December 15, 2019[107]. - The total number of shares held by the top ten shareholders includes significant pledges, indicating potential liquidity risks[104]. - The company completed the annual equity distribution for 2016, resulting in an increase of 27,195,513 shares for Chen Dekang and 2,400,000 shares for Hu Zhengguo[113]. - The total number of ordinary shareholders was 24,767 as of the end of the reporting period[102]. Financial Performance - The company's operating revenue for the first half of the year was ¥416,852,067.20, a decrease of 11.29% compared to ¥469,914,732.30 in the same period last year[22]. - The net profit attributable to shareholders was ¥83,196,353.09, down 20.26% from ¥104,338,326.89 year-on-year[22]. - The basic earnings per share decreased by 26.09% to ¥0.34 from ¥0.46 in the previous year[23]. - The weighted average return on equity dropped by 6.07 percentage points to 5.09% from 11.16%[24]. - The total profit amounted to CNY 98.74 million, reflecting a year-on-year decline of 18.65%[44]. - The company reported a significant decrease in short-term borrowings, indicating improved liquidity management[121]. - The company reported a comprehensive income of 88,108,968.67 CNY for the current period[145]. - The total comprehensive income for the first half of the year was CNY 104,338,326.89, highlighting the company's earnings performance[141]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,762,921,443.66, a decrease of 4.30% from ¥1,842,116,182.80 at the end of the previous year[22]. - Cash and cash equivalents decreased by 50.09% to ¥241,985,004.86, primarily due to the purchase of bank wealth management products[54]. - Accounts receivable decreased by 33.37% to ¥106,940,637.93, attributed to reduced revenue and lower bill collections[54]. - Inventory increased by 44.57% to ¥90,955,868.55, mainly due to an increase in inventory at Shapais Pharmaceutical[54]. - The company’s total liabilities decreased significantly, with a notable reduction in employee compensation liabilities by 57.79%[54]. - Total assets decreased from CNY 1,842,116,182.80 at the beginning of the period to CNY 1,762,921,443.66 at the end, representing a decline of approximately 4.3%[120]. - Total liabilities decreased from CNY 247,882,725.35 to CNY 160,052,411.51, a decline of about 35.5%[121]. Operational Challenges and Risks - The company has outlined potential risks in its operations, which are detailed in the report[6]. - The implementation of various policies in the pharmaceutical industry poses challenges, but also opportunities for growth due to increasing healthcare demands[33]. - The company faces significant risks from industry policies, including drug price reductions due to centralized procurement and strict medical insurance cost control measures[62][63]. - The company is at risk of losing tax benefits if it fails to maintain its status as a high-tech enterprise, which could impact its net profit[66]. - New drug development poses high risks due to long cycles and significant investment, necessitating careful project evaluation and market research[68]. Research and Development - R&D expenditure was CNY 11.26 million, a decrease of 6.18% from the previous year[49]. - The company is focusing on expanding its product line and enhancing R&D capabilities to drive future growth[123]. - The company plans to explore strategic acquisitions to enhance market presence and operational efficiency[123]. Corporate Governance and Compliance - The board of directors and senior management have confirmed the accuracy and completeness of the financial report[2]. - The company has committed to compensating investors for any losses incurred due to false statements or omissions in its prospectus[78]. - The company will take legal measures to fulfill all commitments made during the IPO process and will accept supervision from regulatory bodies and investors[81]. - The company has not reported any significant changes in profit sources or non-main business profit impacts during the reporting period[52]. - There were no significant lawsuits or arbitration matters reported during the reporting period[86]. Market and Industry Overview - The pharmaceutical industry saw a 12.6% year-on-year increase in main business income, totaling ¥14,516.4 billion in the first half of 2017[34]. - The drug terminal market sales in China reached ¥8,037 billion, growing by 7.8% year-on-year, with public hospitals holding the largest market share at 68.1%[34]. - The company focuses on chemical preparations and traditional Chinese medicine, with key products including eye drops and herbal capsules[28]. Accounting Policies and Financial Reporting - The financial report for the half-year period has not been audited[4]. - The company’s financial statements comply with the requirements of the enterprise accounting standards, reflecting the financial position, operating results, changes in shareholders' equity, and cash flows accurately[153]. - The company uses a 12-month cycle as the standard for classifying the liquidity of assets and liabilities due to the short operating cycle[155]. - The company adopts specific accounting policies for the recognition of revenue, depreciation of fixed assets, and amortization of intangible assets[157].